Cargando…

Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome

BACKGROUND: It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. METHODS: To investigate its relationship with the outcome of HCV standard combination the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mylopoulou, Theodora, Papadopoulos, Vasileios, Kassela, Katerina, Karakasiliotis, Ioannis, Souvalidou, Fani, Mimidis, Panagiotis, Veletza, Stavroula, Mavromara, Penelope, Mimidis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102464/
https://www.ncbi.nlm.nih.gov/pubmed/30174396
http://dx.doi.org/10.20524/aog.2018.0290
_version_ 1783349169139744768
author Mylopoulou, Theodora
Papadopoulos, Vasileios
Kassela, Katerina
Karakasiliotis, Ioannis
Souvalidou, Fani
Mimidis, Panagiotis
Veletza, Stavroula
Mavromara, Penelope
Mimidis, Konstantinos
author_facet Mylopoulou, Theodora
Papadopoulos, Vasileios
Kassela, Katerina
Karakasiliotis, Ioannis
Souvalidou, Fani
Mimidis, Panagiotis
Veletza, Stavroula
Mavromara, Penelope
Mimidis, Konstantinos
author_sort Mylopoulou, Theodora
collection PubMed
description BACKGROUND: It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. METHODS: To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. RESULTS: Twenty-nine patients were cirrhotic (stiffness >12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). CONCLUSION: The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection.
format Online
Article
Text
id pubmed-6102464
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-61024642018-09-01 Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome Mylopoulou, Theodora Papadopoulos, Vasileios Kassela, Katerina Karakasiliotis, Ioannis Souvalidou, Fani Mimidis, Panagiotis Veletza, Stavroula Mavromara, Penelope Mimidis, Konstantinos Ann Gastroenterol Original Article BACKGROUND: It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. METHODS: To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. RESULTS: Twenty-nine patients were cirrhotic (stiffness >12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). CONCLUSION: The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection. Hellenic Society of Gastroenterology 2018 2018-07-13 /pmc/articles/PMC6102464/ /pubmed/30174396 http://dx.doi.org/10.20524/aog.2018.0290 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mylopoulou, Theodora
Papadopoulos, Vasileios
Kassela, Katerina
Karakasiliotis, Ioannis
Souvalidou, Fani
Mimidis, Panagiotis
Veletza, Stavroula
Mavromara, Penelope
Mimidis, Konstantinos
Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
title Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
title_full Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
title_fullStr Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
title_full_unstemmed Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
title_short Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
title_sort relationship between antibodies to hepatitis c virus core+1 protein and treatment outcome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102464/
https://www.ncbi.nlm.nih.gov/pubmed/30174396
http://dx.doi.org/10.20524/aog.2018.0290
work_keys_str_mv AT mylopouloutheodora relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT papadopoulosvasileios relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT kasselakaterina relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT karakasiliotisioannis relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT souvalidoufani relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT mimidispanagiotis relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT veletzastavroula relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT mavromarapenelope relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome
AT mimidiskonstantinos relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome